

NOTICE TO THE HOLDERS

of

Trigger Yield Equity-linked Securities due July 2023

linked to Johnson & Johnson, Merck & Co. Inc., Sanofi SA and Glaxosmithkline PLC

ISIN: XS2188592591

(the “Securities”)

issued by Credit Suisse AG, acting through its London Branch (the “Issuer”) under its Trigger Redeemable and Phoenix Securities Base Prospectus in respect of the Structured Products Programme for the issuance of Notes, Certificates and Warrants of the Issuer

The Issuer has issued the Securities pursuant to the Final Terms relating to the Securities dated 7 July 2020, which comprises the final terms of the Securities and must be read in conjunction with the Base Prospectus referred to therein (the “**Base Prospectus**”).

Capitalised terms used but not otherwise defined herein shall have the meanings given to such terms in the Final Terms and the Base Prospectus.

NOTICE IS HEREBY GIVEN to the holders of the Securities that on 1 March 2022, the Luxembourg Stock Exchange (the “**Exchange**”) notified Credit Suisse AG that due to the temporary suspension of settlement in Russian rouble trades, the Exchange had decided to suspend the listing and trading of certain securities issued by the Issuer (including the Securities), effective from 28th February 2022. The suspension was announced on the Exchange’s website (www.bourse.lu).

Securityholders should consult their own advisors in relation to the implications of the suspension of the listing and trading of the Securities on their personal circumstances.

Dated 14th March 2022

Issued by: Credit Suisse AG, acting through its London Branch